SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review

Neurol Sci. 2022 Sep;43(9):5165-5168. doi: 10.1007/s10072-022-06182-w. Epub 2022 Jun 6.

Abstract

Background: Several neurological complications have been reported following SARS-Cov-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening of Parkinson's disease (PD) symptoms and new onset of movement disorders in non-parkinsonian patients.

Methods: We describe two new cases of PD patients treated with device-aided therapy who developed worsening of parkinsonian symptoms after receiving the third vaccine dose (booster). We also conducted a short review of the cases reported in literature of PD symptoms worsening and new onset of movement disorders in non-parkinsonian patients after SARS-Cov-2 vaccination.

Results: The first patient, a 46-year-old man implanted with bilateral Subthalamic Deep Brain Stimulation, experienced temporary motor and non-motor symptoms worsening after mRNA-1273 booster, improved after stimulation settings modification. The second patient, a 55-year-old man implanted with percutaneous endoscopic transgastric jejunostomy (PEG-J) for levodopa-carbidopa intestinal gel (LCIG) infusion experienced severe temporary worsening of dyskinesia and managed through temporary LCIG dose reduction. Other seven cases of vaccine-related movement disorder are currently reported in literature, four describing PD symptoms worsening and three the onset of new movement disorders in otherwise healthy people.

Conclusion: Both our patients and the cases described so far completely recovered after few days with parkinsonian therapy modification, symptomatic treatment, or even spontaneously, underlining the transient and benign nature of side effects from vaccine. Patients should be reassured about these complications, manageable through a prompt evaluation by the reference neurologist.

Keywords: Booster vaccination; COVID-19 vaccine; Movement disorders; Parkinson’s disease.

Publication types

  • Case Reports
  • Review

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Carbidopa / therapeutic use
  • Deep Brain Stimulation
  • Drug Combinations
  • Humans
  • Immunization, Secondary / adverse effects
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Movement Disorders* / etiology
  • Movement Disorders* / therapy
  • Parkinson Disease* / etiology
  • Parkinson Disease* / therapy
  • Treatment Outcome
  • Vaccination* / adverse effects

Substances

  • COVID-19 Vaccines
  • Drug Combinations
  • Levodopa
  • Carbidopa